Concepedia

Publication | Open Access

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

DOIFull Paper Access

166

Citations

26

References

2016

Year

Yasushi Honda, Kento Imajo, Takayuki Kato, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Shingo Kato, Hironori Mawatari, Koji Fujita, Masato Yoneda,
PLoS ONE

Abstract

Ipragliflozin improved the pathogenesis of NASH by reducing insulin resistance and lipotoxicity in NASH-model mice. Our results suggest that ipragliflozin has a therapeutic effect on NASH with T2DM.

References

YearCitations

Page 1